Wayne Kuznar
Wayne Kuznar is a contributor to Urology Times.
RT, hormonal combo treatment reduces prostate cancer mortality
Adding local radiotherapy to hormonal treatment more than halves long-term prostate cancer-specific mortality and substantially decreases overall mortality in men with non-metastatic locally advanced or high-risk prostate cancer, according to an updated analysis of clinical trial data from the Scandinavian Prostate Cancer Group’s Study VII.
No link found between testosterone replacement therapy, prostate cancer risk
Testosterone replacement therapy (TRT) in hypogonadal men does not appear to increase the risk for prostate cancer, according to an evaluation of 224 men with an indication for prostate biopsy, providing further evidence that TRT need not be avoided in this patient group.
Post-abiraterone enzalutamide use viable in some men
Post-abiraterone enzalutamide use viable in some men
Although the activity of enzalutamide (XTANDI) is blunted in patients with metastatic castration-resistant prostate cancer who have been treated previously with abiraterone acetate (ZYTIGA), a meaningful number of these patients still experience a decline in PSA level with enzalutamide, according to a recent study.
Prostate cancer agent fails to extend survival in phase III trial
Prostate cancer agent fails to extend survival in phase III trial
The investigational 17,20 lyase inhibitor orteronel failed to significantly extend overall survival in an international phase III study of patients with metastatic castration-resistant prostate cancer.
New prostate cancer tests mark era of personalized medicine
A new generation of prostate cancer biomarkers promises to alter the way in which urologists make clinical management decisions.
Anti-androgen shows benefit in pre-chemo setting
Anti-androgen shows benefit in pre-chemo setting
The second-generation androgen receptor antagonist enzalutamide (XTANDI) significantly improved survival and delayed the time to chemotherapy in men with previously untreated metastatic castrate-resistant prostate cancer, according to a recent study.
Body composition unchanged after advanced prostate cancer treatment
No differences in body composition were found among metastatic castration-resistant prostate cancer patients taking abiraterone acetate (ZYTIGA), enzalutamide (Xtandi), or placebo who were treated as part of two clinical trials.
Waiting to start salvage radiation therapy safe, according to study
Outcomes following salvage radiation therapy after recurrent prostate cancer in a racially mixed cohort are no better when it’s started at a PSA level <0.5 ng/mL compared with a level <1.0 ng/mL.
Pre-Dx aspirin use linked to reduced prostate cancer mortality
Regular use of aspirin in the year before a diagnosis of stage I-III prostate cancer is associated with a reduction in prostate cancer-specific mortality, say Irish researchers.
Convenience affects prostate cancer treatment choice
African-American men are more influenced by convenience than are Caucasian men in their choice of treatment for early-stage prostate cancer, according to a recent study.

Poll

View Results